Skip to main content

Paralysis

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

NeuroTrigger
NeuroTriggerIsrael - Tel Aviv
1 program
Neurotrigger Basic. eye blinking stimulatorN/A1 trial
Active Trials
NCT06069128Completed11Est. Sep 2024
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Transcutaneous Electrical Spinal Cord StimulationN/A1 trial
Active Trials
NCT01906424Completed7Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NeuroTriggerNeurotrigger Basic. eye blinking stimulator
Angeles TherapeuticsTranscutaneous Electrical Spinal Cord Stimulation

Clinical Trials (2)

Total enrollment: 18 patients across 2 trials

NCT06069128NeuroTriggerNeurotrigger Basic. eye blinking stimulator

Evaluate the Usability of the Neuro-trigger Artificial Eye Blinking Stimulation Device in Patients With Paralysis of the Facial Nerve.

Start: Oct 2023Est. completion: Sep 202411 patients
N/ACompleted
NCT01906424Angeles TherapeuticsTranscutaneous Electrical Spinal Cord Stimulation

Restoring Arm and Hand Function With Non-invasive Spinal Stimulation

Start: Apr 2016Est. completion: Dec 20167 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.